Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

Frölich, Lutz ; Peters, Oliver ; Lewczuk, Piotr ; Gruber, Oliver ; Teipel, Stefan J. ; Gertz, Hermann J. ; Jahn, Holger ; Jessen, Frank ; Kurz, Alexander ; Luckhaus, Christian ; Hüll, Michael ; Pantel, Johannes ; Reischies, Friedel M. ; Schröder, Johannes ; Wagner, Michael ; Rienhoff, Otto ; Wolf, Stefanie ; Bauer, Chris ; Schuchhardt, Johannes ; Heuser, Isabella ; Rüther, Eckart ; Henn, Fritz ; Maier, Wolfgang ; Wiltfang, Jens ; Kornhuber, Johannes

In: Alzheimer's Research & Therapy, 9 (2017), Nr. 84. pp. 1-15. ISSN 1758-9193

[thumbnail of 13195_2017_Article_301.pdf]
Preview
PDF, English
Download (874kB) | Lizenz: Creative Commons LizenzvertragIncremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia by Frölich, Lutz ; Peters, Oliver ; Lewczuk, Piotr ; Gruber, Oliver ; Teipel, Stefan J. ; Gertz, Hermann J. ; Jahn, Holger ; Jessen, Frank ; Kurz, Alexander ; Luckhaus, Christian ; Hüll, Michael ; Pantel, Johannes ; Reischies, Friedel M. ; Schröder, Johannes ; Wagner, Michael ; Rienhoff, Otto ; Wolf, Stefanie ; Bauer, Chris ; Schuchhardt, Johannes ; Heuser, Isabella ; Rüther, Eckart ; Henn, Fritz ; Maier, Wolfgang ; Wiltfang, Jens ; Kornhuber, Johannes underlies the terms of Creative Commons Attribution 3.0 Germany

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive power. We investigated which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery, hippocampal volume (HCV), amyloid-beta1–42 (Aβ42), amyloid-beta1–40 (Aβ40) levels, the ratio of Aβ42/Aβ40, phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD dementia. Methods We used 115 complete datasets from MCI patients of the “Dementia Competence Network”, a German multicenter cohort study with annual follow-up up to 3 years. MCI was broadly defined to include amnestic and nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%. Results Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of 25.5 months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but had lower educational attainment. All single biomarkers were significantly different between the two groups at baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all single predictors were statistically superior to Aβ40. The AUC of the two-parameter combinations ranged from 0.77 to 0.81. The three-parameter combinations ranged from AUC 0.80–0.83, and the four-parameter combination from AUC 0.81–0.82. None of the predictor combinations was significantly superior to the two best single predictors (HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter combinations were superior to HCV alone. Conclusion A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there is a gradual increase in the statistical measures across increasing biomarker combinations. This may have implications for clinical diagnosis and for selecting subjects for participation in clinical trials.

Document type: Article
Journal or Publication Title: Alzheimer's Research & Therapy
Volume: 9
Number: 84
Publisher: Biomed Central
Place of Publication: London
Date Deposited: 23 Oct 2017 07:49
Date: 2017
ISSN: 1758-9193
Page Range: pp. 1-15
Faculties / Institutes: Service facilities > Zentralinstitut für Seelische Gesundheit
Medizinische Fakultät Heidelberg > Psychiatrische Universitätsklinik
DDC-classification: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative